Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Uveal Melanoma
Recruiting3 awardsPhase 2
Portland, Oregon
This trial is testing a combination of two drugs, lenvatinib and pembrolizumab, to treat adults with metastatic uveal melanoma. Lenvatinib is taken as a daily pill, and pembrolizumab is given through an IV periodically. The goal is to see if these drugs can stop cancer growth and help the immune system fight the cancer. Pembrolizumab is an immune checkpoint inhibitor that has shown promise in treating various cancers, including melanoma, by enhancing the immune system's ability to fight cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service